{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T02:32:14Z","timestamp":1770690734085,"version":"3.49.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.yrtph.2021.104889","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T04:38:23Z","timestamp":1613363903000},"page":"104889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Preclinical safety evaluation of nafithromycin (WCK 4873) with emphasis on liver safety in rat and dog"],"prefix":"10.1016","volume":"122","author":[{"given":"Manohar","family":"Nandanwar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5611-5251","authenticated-orcid":false,"given":"Rajesh","family":"Chavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Kansagara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muftedar Ahmed","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anasuya","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravindra","family":"Yeole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2021.104889_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1055\/s-2002-30103","article-title":"Hepatotoxicity of antimicrobial agents","volume":"22","author":"Brown","year":"2002","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.yrtph.2021.104889_bib2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/hep.22620","article-title":"Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases","volume":"49","author":"Brinker","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.yrtph.2021.104889_bib3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.7326\/0003-4819-144-6-200503210-00121","article-title":"Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review","volume":"144","author":"Clay","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.yrtph.2021.104889_bib4","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1517\/13543784.2014.954036","article-title":"The wobbly status of ketolides: where do we stand?","volume":"23","author":"Georgopapadakou","year":"2014","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.yrtph.2021.104889_bib5","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2174\/138161210791208910","article-title":"In vitro evaluation of potential hepatotoxicity induced by drugs","volume":"16","author":"G\u00f3mez-Lech\u00f3n","year":"2010","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.yrtph.2021.104889_bib6","series-title":"Harmonized Tripartite Guide Line S3A: Note for Guidance on Toxicokinetics: the Assessment of Systemic Exposure in Toxicity Studies","author":"International Conference on Harmonization","year":"1994"},{"key":"10.1016\/j.yrtph.2021.104889_bib7","series-title":"Harmonised Tripartite Guide Line M3(R2) : Guidance on NonClinical Safety Stud Ies for the Conduct of Human Clinical Trial S and Marketing Authorization for Pharmaceuticals","author":"International Conference on Harmonisation","year":"2009"},{"key":"10.1016\/j.yrtph.2021.104889_bib8","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2174\/1389200219666180523095355","article-title":"Models of drug induced liver injury (DILI) - current issues and future perspectives","volume":"19","author":"Kuna","year":"2018","journal-title":"Curr drug Metab"},{"key":"10.1016\/j.yrtph.2021.104889_bib9","series-title":"Tablet. Product Monograph","author":"Ketek (Telithromycin)","year":"2007"},{"key":"10.1016\/j.yrtph.2021.104889_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01474-17","article-title":"Metabolism, excretion and mass balance of solithromycin in human","volume":"62","author":"MacLauchlin","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.yrtph.2021.104889_bib11","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1124\/dmd.32.6.647","article-title":"Validated assays for human cytochrome p450 activities","volume":"32","author":"Obach","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.yrtph.2021.104889_bib12","first-page":"103","article-title":"Oral repeated-dose toxicity studies and toxicokinetic studies of telithromycin in rats","volume":"51","author":"Omosu","year":"2003","journal-title":"Jpn. J. Chemother."},{"key":"10.1016\/j.yrtph.2021.104889_bib13","first-page":"115","article-title":"Oral repeated-dose toxicity studies and toxicokinetic studies of telithromycin in beagle dogs and cynomolgus monkeys","volume":"51","author":"Omosu","year":"2003","journal-title":"Jpn. J. Chemother."},{"key":"10.1016\/j.yrtph.2021.104889_bib14","series-title":"Meeting of the Antimicrobial Drugs Advisory Committee","article-title":"FDA briefing document","author":"Solithromycin Oral Capsule and Injection","year":"2016"},{"key":"10.1016\/j.yrtph.2021.104889_bib15","series-title":"Committee for Medicinal Products for Human Use (CHMP)","author":"Solithromycin Assessment report","year":"2017"},{"key":"10.1016\/j.yrtph.2021.104889_bib16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11095-019-2582-y","article-title":"Analyzing the mechanisms behind macrolide antibiotic-induced liver injury using quantitative systems toxicology modeling","volume":"36","author":"Woodhead","year":"2019","journal-title":"Pharm. Res. (N. Y.)"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230021000295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230021000295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:30:09Z","timestamp":1759494609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230021000295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":16,"alternative-id":["S0273230021000295"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2021.104889","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical safety evaluation of nafithromycin (WCK 4873) with emphasis on liver safety in rat and dog","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2021.104889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104889"}}